You are here: Industry Insights > Eli Lilly

News List

Patent fights jump in 2017 as Eli Lilly, Pfizer, Sanofi and more sue to protect their meds fiercepharma
May 07, 2018
In the ever-raging war between generic drugmakers and branded pharma, patent litigation is a standard-issue weapon. It's a high-stakes business as generics makers aim to grow their sales by rolling out copies of blockbuster drugs...
French Insulin Maker Spurned by Eli Lilly Forges Deal with China’s Tonghua Dongbao biospace
April 27, 2018
Shares of Adocia are up nearly 30 percent this morning after the French company announced it granted exclusive development and commercialization rights of its insulin products to Tonghua Dongbao Pharmaceuticals
Overseas Partnerships: Eli Lilly Forges Chinese Diabetes Collaboration biospace
April 26, 2018
China continues to be a hotbed of investment for U.S. pharmaceutical and biotech companies
Eli Lilly lifts annual guidance as first-quarter prescription drug sales rise 11 percent firstwordpharma
April 25, 2018
Eli Lilly reported Tuesday that first-quarter revenue from prescription drugs climbed 11 percent year-over-year, led by growth from new products.
Eli Lilly’s Arthritis Drug Gets Mixed Recommendation, But Reports Strong Quarter biospace
April 25, 2018
Last week, briefing documents related to the U.S. Food and Drug Administration (FDA)’s advisory committee review of Eli Lilly and Incyte’s baricitinib for rheumatoid arthritis expressed safety concerns.
Eli Lilly and Incyte Shares Drop as FDA Raises Concerns about Arthritis Drug biospace
April 20, 2018
Ahead of next Monday’s U.S. Food and Drug Administration (FDA)committee review of Eli Lilly and Incyte’s baricitinib for rheumatoid arthritis, concerns over blood clots, may scuttle the drug’s chances.
Eli Lilly Shows Off More Verzenio Data at AACR biospace
April 19, 2018
Eli Lilly unveiled final data from the MONARCH 3 trial that won the latest nod from the U.S. Food and Drug Administration for the treatment of some breast cancer patients.
Eli Lilly Gets Another Shot at FDA Approval for RA Drug biospace
March 16, 2018
In April 2017, the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) for Eli Lilly and Company and Incyte Corporation’s baricitinib for moderate-to-severe rheumatoid arthritis (RA).
Lilly Reports Strong Fourth-Quarter and Full-Year 2017 Revenue Growth, Increases 2018 EPS Guidance biospace
February 01, 2018
Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2017.
Eli Lilly's Taltz get EU approval in psoriatic arthritis subgroup pharmafile
January 25, 2018
Eli Lilly revealed that its IgG4 monoclonal antibody Taltz (ixekizumab) has been approved by the European Commission for the treatment of patients with active Psoriatic Arthritis (PsA)

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page